Biomanufacturing

Single-use bioreactors eliminate cleaning validation between batches. Continuous manufacturing maintains cells in steady state for consistent production. Process analytical technology (PAT) monitors quality in real time. Automated cell line development accelerates production organism creation. Cell-free manufacturing produces proteins without living cells for certain applications.

Mammalian cell culture produces monoclonal antibodies for cancer treatment. mRNA manufacturing produces COVID vaccines at unprecedented scale. Microbial fermentation produces insulin, growth hormones, and industrial enzymes. Cell therapy manufacturing processes patient cells for CAR-T treatment. Precision fermentation produces food proteins without animals.

The global biomanufacturing market exceeds $400 billion, with biopharmaceutical manufacturing (antibodies, vaccines, cell/gene therapies) comprising the largest segment. Bio-based chemicals and materials represent a fast-growing but smaller segment.